Browse our latest Cancer Biology articles

Remdesivir is a promising treatment modality to reduce 30 day all-cause mortality.

Long COVID occurred in the majority of cancer patients diagnosed with acute COVID-19 with a preponderance of symptoms (such as fatigue, sleep disturbances, and gastrointestinal symptoms) over a long time period.

Multi-omic profiling of tumor-infiltrating T cells provides new insights into the differences in the effectiveness of CDK4 inhibitor between human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinoma patients.

As macrophages are involved in various aspects of non-small cell lung cancer development and progression it is crucial to develop appropriate 3D co-culture platforms for modeling immune cell-tumor cell interactions, leading to more efficacious macrophage-focused immunotherapies.

Protein kinase A-driven increases in c-MYC protein expression and tumor cell proliferation can be blocked by eIF4A inhibitors, suggesting a potential new treatment option for patients with oncogenic PKA activation.

Deregulated cell fate specification pathways, including oncogenic Ras, cause activation of JNK-signaling at contact sites with wild type cells, which drives apoptosis and aberrant cell elimination in a contact-dependent manner.

The rational drug design combining the bioassay identified a novel selective androgen receptor (AR) degrader for both AR and AR-VRs and illustrated the synergistic importance of AR antagonism and degradation in advanced prostate cancer treatment.

ELYS, a multifunctional protein with critical roles in the cell cycle, is essential for the vigorous proliferation and survival of difficult-to-treat cancers carrying mutations in the KRAS oncogene, making it a compelling target for novel drug treatments.

Human papillomavirus type 8 E6 promotes alternative end joining by compromising non-homologous end joining and homologous recombination.